다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of gastric cancer : jgc, v.23 no.1, 2023년, pp.207 - 223
Jeesun Yoon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) , Tae-Yong Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) , Do-Youn Oh (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
AI-Helper
Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under the standard of care, patients with advanced GC (AGC) have a median survival time of approximately 12-15 months. With the emergence of immunotherapy as a key therapeutic strategy in medical oncology, relevant c...
1 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 249 33538338
3 Cunningham D Starling N Rao S Iveson T Nicolson M Coxon F Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 2008 358 36 46 18172173
4 Bang YJ Van Cutsem E Feyereislova A Chung HC Shen L Sawaki A Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 2010 376 687 697 20728210
5 Mellman I Coukos G Dranoff G Cancer immunotherapy comes of age Nature 2011 480 480 489 22193102
6 Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 264 22437870
7 Lawrence MS Stojanov P Polak P Kryukov GV Cibulskis K Sivachenko A Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 2013 499 214 218 23770567
8 Kono K Nakajima S Mimura K Current status of immune checkpoint inhibitors for gastric cancer Gastric Cancer 2020 23 565 578 32468420
9 Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma Nature 2014 513 202 209 25079317
10 Massarelli E Papadimitrakopoulou V Welsh J Tang C Tsao AS Immunotherapy in lung cancer Transl Lung Cancer Res 2014 3 53 63 25806281
11 Ralli M Botticelli A Visconti IC Angeletti D Fiore M Marchetti P Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions J Immunol Res 2020 2020 9235638 32671117
12 Takei S Kawazoe A Shitara K The new era of immunotherapy in gastric cancer Cancers (Basel) 2022 14 1054 35205802
13 Kang YK Boku N Satoh T Ryu MH Chao Y Kato K Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2017 390 2461 2471 28993052
14 Fuchs CS Doi T Jang RW Muro K Satoh T Machado M Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial JAMA Oncol 2018 4 e180013 29543932
15 Janjigian YY Shitara K Moehler M Garrido M Salman P Shen L First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 2021 398 27 40 34102137
16 Shitara K Ajani JA Moehler M Garrido M Gallardo C Shen L Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer Nature 2022 603 942 948 35322232
17 Hindson J KEYNOTE-811: pembrolizumab in advanced HER2 + gastric cancer Nat Rev Gastroenterol Hepatol 2022 19 79
18 Janjigian YY Kawazoe A Yañez P Li N Lonardi S Kolesnik O The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer Nature 2021 600 727 730 34912120
19 Vafaei S Zekiy AO Khanamir RA Zaman BA Ghayourvahdat A Azimizonuzi H Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier Cancer Cell Int 2022 22 2 34980128
20 Lwin Z Gomez-Roca C Saada-Bouzid E Yanez E Muñoz FL Im SA LEAP-005: phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours Ann Oncol 2020 31 S1170 S1170
21 Pavlakis N Shitara K Sjoquist K Martin AJ Jaworski A Yip S INTEGRATE IIb: a randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC) Ann Oncol 2021 32 S1074 S1074
22 Bang YJ Van Cutsem E Fuchs CS Ohtsu A Tabernero J Ilson DH KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer Future Oncol 2019 15 943 952 30777447
23 Smyth E Knödler M Giraut A Mauer M Nilsson M Van Grieken N VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study Front Oncol 2020 9 1320 32083013
24 Chao J Fuchs CS Shitara K Tabernero J Muro K Van Cutsem E Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials JAMA Oncol 2021 7 895 902 33792646
25 Pietrantonio F Randon G Di Bartolomeo M Luciani A Chao J Smyth EC Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials ESMO Open 2021 6 100036 33460964
26 Puliga E Corso S Pietrantonio F Giordano S Microsatellite instability in Gastric Cancer: between lights and shadows Cancer Treat Rev 2021 95 102175 33721595
27 Shitara K Özgüroğlu M Bang YJ Di Bartolomeo M Mandalà M Ryu MH Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Lancet 2018 392 123 133 29880231
28 Bang YJ Ruiz EY Van Cutsem E Lee KW Wyrwicz L Schenker M Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 Ann Oncol 2018 29 2052 2060 30052729
29 Shitara K Van Cutsem E Bang YJ Fuchs C Wyrwicz L Lee KW Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial JAMA Oncol 2020 6 1571 1580 32880601
30 Kang YK Chen LT Ryu MH Oh DY Oh SC Chung HC Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 2022 23 234 247 35030335
31 Xu R Arkenau T Bang Y Denlinger C Kato K Tabernero J RATIONALE 305: tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma Ann Oncol 2020 31 S97 S98
32 Tabernero J Bang YJ Van Cutsem E Fuchs CS Janjigian YY Bhagia P KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma Future Oncol 2021 17 2847 2855 33975465
33 Catenacci DV Rosales M Chung HC H Yoon H Shen L Moehler M MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma Future Oncol 2021 17 1155 1164 33263418
34 Tabernero J Shen L Elimova E Ku G Liu T Shitara K HERIZON-GEA-01: zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma Future Oncol 2022 18 3255 3266 36000541
35 Catenacci DVT Kang YK Yoon HH Shim BY Kim ST Oh DY Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A ESMO Open 2022 7 100563 36029651
36 Bang YJ Cho JY Kim YH Kim JW Di Bartolomeo M Ajani JA Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer Clin Cancer Res 2017 23 5671 5678 28655793
37 Moehler M Dvorkin M Boku N Özgüroğlu M Ryu MH Muntean AS Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100 J Clin Oncol 2021 39 966 977 33197226
38 Cohen DJ Tabernero J Van Cutsem E Janjigian YY Bang YJ Qin S A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 J Clin Oncol 2022 40 TPS369
39 Terashima M Kim YW Yeh TS Chung HC Chen JS Boku N ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo- controlled phase 3 study of nivolumab (nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer Ann Oncol 2017 28 v266 v267
40 Janjigian YY Van Cutsem E Muro K Wainberg Z Al-Batran SE Hyung WJ MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer Future Oncol 2022 18 2465 2473
41 Ono Pharmaceutical Co. Ltd A study to evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) [Internet] Bethesda (MD) US National Library of Medicine 2022 cited 2022 Sep 13 Available from: https://clinicaltrials.gov/ct2/show/NCT05144854
42 Chen LT Satoh T Ryu MH Chao Y Kato K Chung HC A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Gastric Cancer 2020 23 510 519 31863227
43 Boku N Satoh T Ryu MH Chao Y Kato K Chung HC Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Gastric Cancer 2021 24 946 958 33743112
44 Varayathu H Sarathy V Thomas BE Mufti SS Naik R Combination strategies to augment immune check point inhibitors efficacy - implications for translational research Front Oncol 2021 11 559161 34123767
45 Salas-Benito D Pérez-Gracia JL Ponz-Sarvisé M Rodriguez-Ruiz ME Martínez-Forero I Castañón E Paradigms on immunotherapy combinations with chemotherapy Cancer Discov 2021 11 1353 1367 33712487
46 Heinhuis KM Ros W Kok M Steeghs N Beijnen JH Schellens JH Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors Ann Oncol 2019 30 219 235 30608567
47 Kim R An M Lee H Mehta A Heo YJ Kim KM Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer Cancer Discov 2022 12 984 1001 34933901
48 BeiGene BeiGene announces positive findings from phase 3 trial of tislelizumab in combination with chemotherapy in first-line gastric or gastroesophageal junction cancer [Internet] Beijing BeiGene 2022 cited 2022 Jan 24 Available from: https://ir.beigene.com/news/beigene-announces-positive-findings-from-phase-3-trial-of-tislelizumab-in-combination-with-chemotherapy-in/b8b9f75d-c374-4593-95c0-ed8bd3e649cb/
49 Maadi H Soheilifar MH Choi WS Moshtaghian A Wang Z Trastuzumab mechanism of action; 20 years of research to unravel a dilemma Cancers (Basel) 2021 13 3540 34298754
50 Murciano-Goroff YR Warner AB Wolchok JD The future of cancer immunotherapy: microenvironment-targeting combinations Cell Res 2020 30 507 519 32467593
51 Janjigian YY Bendell J Calvo E Kim JW Ascierto PA Sharma P CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer J Clin Oncol 2018 36 2836 2844 30110194
52 Hanahan D Hallmarks of cancer: new dimensions Cancer Discov 2022 12 31 46 35022204
53 Fukuoka S Hara H Takahashi N Kojima T Kawazoe A Asayama M Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) J Clin Oncol 2020 38 2053 2061 32343640
54 Kole C Charalampakis N Tsakatikas S Kouris NI Papaxoinis G Karamouzis MV Immunotherapy for gastric cancer: a 2021 update Immunotherapy 2022 14 41 64 34784774
55 Maio M Ascierto PA Manzyuk L Motola-Kuba D Penel N Cassier PA Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study Ann Oncol 2022 33 929 938 35680043
56 Lima Á Sousa H Medeiros R Nobre A Machado M PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis Discov Oncol 2022 13 19 35318527
57 Xie T Liu Y Zhang Z Zhang X Gong J Qi C Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study J Immunother 2020 43 139 144 32134806
58 Bai Y Xie T Wang Z Tong S Zhao X Zhao F Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer J Immunother Cancer 2022 10 e004080 35241494
59 Schoemig-Markiefka B Eschbach J Scheel AH Pamuk A Rueschoff J Zander T Optimized PD-L1 scoring of gastric cancer Gastric Cancer 2021 24 1115 1122 33954872
60 Xie T Zhang Z Zhang X Qi C Shen L Peng Z Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: a systematic review and meta-analysis Front Oncol 2021 11 646355 34540656
61 Zhao JJ Yap DW Chan YH Tan BK Teo CB Syn NL Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma J Clin Oncol 2022 40 392 402 34860570
62 Samstein RM Lee CH Shoushtari AN Hellmann MD Shen R Janjigian YY Tumor mutational load predicts survival after immunotherapy across multiple cancer types Nat Genet 2019 51 202 206 30643254
63 Lee KW Van Cutsem E Bang YJ Fuchs CS Kudaba I Garrido M Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study Clin Cancer Res 2022 28 3489 3498 35657979
64 Foote MB Maron SB Cercek A Argilés G Rousseau B Diaz LA Jr TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061 Ann Oncol 2021 32 1188 1189 34139271
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.